|Stage of funding:||Current|
|Therapeutic group:||Inflammatory Diseases|
Celtaxsys is a clinical-stage development company focused on novel therapeutics that treat inflammatory disease through regulation of immune cell migration and activation. The company is building a sustainable pipeline of first-in-class immuno-modulators.
The lead drug candidate, acebilustat is a potent, oral, once-daily, small-molecule LTA4 Hydrolase (LTA4H) inhibitor – the key enzyme in the production of the powerful promoter of inflammation Leukotriene B4 (LTB4). Both LTA4H and LTB4 are strongly implicated in the pathogenesis of pulmonary inflammation in Cystic Fibrosis (CF). Acebilustat has been shown to be effective in several CF-related, pre-clinical and clinical models and has been well tolerated in healthy volunteers and CF patients.
Celtaxsys is located in Atlanta, GA with a subsidiary office in Brisbane, Queensland, Australia.
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 90,000 shares of its common stock to two new employees, with a grant date of June 14, 2018 .
14 June 2018
31 May 2018
30 May 2018